Platinum-based drugs are largely used in cancer treatment. Using genome-wide approaches we aimed at identifying cisplatin primary and secondary targets and at characterizing cisplatin responsive genes.

The yeast Saccharomyces cerevisiae is widely used to study a variety of eukaryotic cellular processes including those that are relevant for human health.

Yeast can be used for genetic, genomic and mechanistic studies as well as for pharmacogenomic approaches. Using yeast-based pharmacogenomic screens we identified novel genes relevant for the cisplatin response. In particular, we have identified genes involved in DNA repair pathways such as Nucleotide Excision Repair, Homologous Recombination and Post Replicative Repair, as well other genes.

We also used mechanistic approaches to further characterize those factors that have obvious human ortologues and whose functions are still elusive.

Altogether our approaches allowed us to unmask novel factors that contribute to cell viability and genome integrity in response to cisplatin treatment. Complementary studies on the human ortologues are ongoing.

Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2190.